Author: Deepika Konatham

1.

Clinical Epidemiology and Risk Factors for Critical Outcomes Among Vaccinated and Unvaccinated Adults Hospitalized With COVID-19-VISION Network, 10 States, June 2021-March 2023

Griggs E, Mitchell P, Lazariu V, Gaglani M, McEvoy C, Klein N, et al.

Clin Infect Dis . 2023 Aug; 78(2):338-348. PMID: 37633258

Background: The epidemiology of coronavirus disease 2019 (COVID-19) continues to develop with emerging variants, expanding population-level immunity, and advances in clinical care. We describe changes in the clinical epidemiology of...

2.

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021

Embi P, Levy M, Patel P, DeSilva M, Gaglani M, Dascomb K, et al.

Vaccine . 2023 Jul; 41(37):5424-5434. PMID: 37479609

Background: Immunocompromised (IC) persons are at increased risk for severe COVID-19 outcomes and are less protected by 1-2 COVID-19 vaccine doses than are immunocompetent (non-IC) persons. We compared vaccine effectiveness...

3.

Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents

Klein N, Demarco M, Fleming-Dutra K, Stockwell M, Kharbanda A, Gaglani M, et al.

Pediatrics . 2023 Apr; 151(5). PMID: 37026401

Objectives: We assessed BNT162b2 vaccine effectiveness (VE) against mild to moderate and severe coronavirus disease 2019 (COVID-19) in children and adolescents through the Omicron BA.4/BA.5 period. Methods: Using VISION Network...

4.

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022

Tenforde M, Weber Z, Natarajan K, Klein N, Kharbanda A, Stenehjem E, et al.

MMWR Morb Mortal Wkly Rep . 2023 Mar; 71(53):1637-1646. PMID: 36921274

During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of the sequenced viral genomes in the United States, with further Omicron sublineage diversification through November 2022.* Bivalent mRNA...

5.

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022

Tenforde M, Weber Z, Natarajan K, Klein N, Kharbanda A, Stenehjem E, et al.

MMWR Morb Mortal Wkly Rep . 2022 Dec; 71(5152):1616-1624. PMID: 36580430

During June-October 2022, the SARS-CoV-2 Omicron BA.5 sublineage accounted for most of the sequenced viral genomes in the United States, with further Omicron sublineage diversification through November 2022.* Bivalent mRNA...

6.

Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States

Schrag S, Verani J, Dixon B, Page J, Butterfield K, Gaglani M, et al.

JAMA Netw Open . 2022 Sep; 5(9):e2233273. PMID: 36156146

Importance: Pregnant people are at high risk for severe COVID-19 but were excluded from mRNA vaccine trials; data on COVID-19 vaccine effectiveness (VE) are needed. Objective: To evaluate the estimated...

7.

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022

Link-Gelles R, Levy M, Gaglani M, Irving S, Stockwell M, Dascomb K, et al.

MMWR Morb Mortal Wkly Rep . 2022 Jul; 71(29):931-939. PMID: 35862287

The Omicron variant (B.1.1.529) of SARS-CoV-2, the virus that causes COVID-19, was first identified in the United States in November 2021, with the BA.1 sublineage (including BA.1.1) causing the largest...

8.

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION...

Klein N, Stockwell M, Demarco M, Gaglani M, Kharbanda A, Irving S, et al.

MMWR Morb Mortal Wkly Rep . 2022 Mar; 71(9):352-358. PMID: 35239634

The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, and 16-17 years (1-3). Limited real-world data...

9.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10...

Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S, et al.

MMWR Morb Mortal Wkly Rep . 2022 Feb; 71(7):255-263. PMID: 35176007

CDC recommends that all persons aged ≥12 years receive a booster dose of COVID-19 mRNA vaccine ≥5 months after completion of a primary mRNA vaccination series and that immunocompromised persons...

10.

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August...

Thompson M, Natarajan K, Irving S, Rowley E, Griggs E, Gaglani M, et al.

MMWR Morb Mortal Wkly Rep . 2022 Jan; 71(4):139-145. PMID: 35085224

Estimates of COVID-19 mRNA vaccine effectiveness (VE) have declined in recent months (1,2) because of waning vaccine induced immunity over time,* possible increased immune evasion by SARS-CoV-2 variants (3), or...